Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jun;7(6):558-560.
doi: 10.1158/2159-8290.CD-17-0087.

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies

Raghav Sundar  1   2 , David S Hong  3 , Scott Kopetz  3 , Timothy A Yap  4
Affiliations
Comment

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies

Raghav Sundar et al. Cancer Discov. 2017 Jun.

Abstract

<b/> BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558-60. ©2017 AACR.See related article by van Geel et al., p. 610.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: DSH has received research support from Genentech. SK has served on Advisory Boards for Genentech, Array, Novartis, and Merck KGA. TAY has received research support from AstraZeneca, Roche and Pfizer, has served on Advisory Boards of Pfizer, Bristol Myers Squibb, Ignyta and Clovis Oncology, and received travel support from Pfizer and Bristol Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Comment on

References

    1. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015;33:4032–8. - PMC - PubMed
    1. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015;33:4023–31. - PMC - PubMed
    1. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3. - PubMed
    1. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373:726–36. - PMC - PubMed
    1. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, et al. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016;6:1352–65. - PMC - PubMed

MeSH terms

Substances